Drug Target Review

DECEMBER 16, 2024

In this interview, she discusses her path to becoming a physician and clinical researcher, the obstacles she faced, and her dedication to improving outcomes for cancer patients. Dr Hingorani also shares insights into the strengths women bring to STEM, the importance of mentorship, and her vision for the future of oncology research.

Medical Schools 52

Medical Schools Clinical Research Drug Development Trials 52

Advarra

FEBRUARY 28, 2023

Rebecca Lee Crumpler Rebecca Lee Crumpler was one of the first African American women to graduate from medical school and to practice medicine. Crumpler’s focus on the care of women and children and her dedication to research led her to publish “A Book of Medical Discourses” in 1883.

Medical Schools 52

Medical Schools Laboratories Clinical Research Treatment 52

Drug Target Review

JUNE 6, 2023

Our goal is to design and develop potentially first- and best-in-class molecules to deliver meaningful clinical benefit across a wide range of cancers, including tumour types where immunotherapies are not yet approved or have not shown efficacy.

Engineering 98

Engineering Immune Response Biochemical Pharmacology Clinical Trials 98

Drug Target Review

FEBRUARY 29, 2024

During my training, I saw US medical school admissions reach parity. Dr Van Laar obtained her MD from the University of Pittsburgh School of Medicine and completed a clinical-research fellowship in Movement Disorders at the University of Pittsburgh Medical Center.

Therapies 111

Therapies Disease Clinical Trials Science 111

The Pharma Data

NOVEMBER 19, 2020

Previously, Baffa was Therapeutic Area Head of Oncology, Global Clinical Development for Shire. Q State – Steven Hyman and Mathew Might joined the Q State Biosciences Board of Directors as independent directors. HotSpot Therapeutics – Eva Jack was named COO of Boston-based HotSpot.

Laboratories 52

Laboratories Research Laboratories Science Organic Chemistry 52

The Pharma Data

NOVEMBER 1, 2020

Trial facilitated with coll a boration of Harvard Medical School and one of the world’s top Neurologist, Dr. Howard Weiner. Clinical Data Expected by End of Year. Highly innovative first-in-class study for treating COVID-19 disease with nasally administered drug.

Clinical Trials 40

Clinical Trials Trials Medical Schools Hospitals 40

The Pharma Data

APRIL 12, 2022

“Data obtained from this exploratory analysis holds promise for potential future clinical research,” said Jacqueline S. Dana-Farber Cancer Institute, assistant professor of medicine at Harvard Medical School. The most common SAEs were pneumonia (n= 4, 12%) and splenic infarction (n= 2, 6%).2 Garcia, M.D.,

Medical Schools 52

Medical Schools Trials Disease Clinical Development 52